NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/organon-co-class-action. Investors have until July 22, 2025, to ask the Court to be appointed to lea ...

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit. Investors have until July 14, 2 ...

Core Viewpoint - A lawsuit has been filed against Civitas Resources, Inc. and its senior executives for potential violations of federal securities laws, specifically under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, captioned Lin v. Civitas Resources, et al., No. 25-cv-03791 [2]. - Investors have until July 1, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - Civitas Resources is an oil and gas exploration and production company with key assets in the Denver-Julesburg Basin in Colorado and the Permian Basin in Texas and New Mexico [3]. - The company claimed to have "enhanced recovery potential" and "driven production ahead of plans," while asserting that costs were below expectations [3]. Group 3: Financial Performance and Stock Impact - On February 24, 2025, Civitas announced disappointing Q4 and full year 2024 results, revealing that oil production had peaked and would require significant capital investment to increase production [4]. - Following the announcement, Civitas's stock price dropped over 18%, from $49.30 per share to $40.35 per share [4].

Key Takeaways Old economy stocks like HWM, NEM, SFM, GE, and CW are rising amid tech sector weakness and market uncertainty. HWM, NEM, and SFM each show double-digit earnings growth and recent estimate upgrades driving investor appeal. GE and CW are capitalizing on defense, aviation, and energy trends while enhancing shareholder returns.The artificial intelligence (AI)-driven, astonishing bull run of 2023 and 2024 has suffered setbacks in 2025. The Fed’s ambiguity over further rate cuts this year, fears o ...

Core Insights - Newmont Corporation (NEM) and Kinross Gold Corporation (KGC) are significant players in the gold mining industry, with global operations and diversified portfolios. Gold prices, while down from April 2025 highs, remain favorable due to safe-haven demand amid trade and geopolitical uncertainties, currently above $3,300 per ounce [1][2]. Gold Market Dynamics - Gold prices have increased approximately 28% this year, driven by aggressive trade policies, global trade tensions, and central bank accumulation of gold reserves. Prices peaked at $3,500 per ounce on April 22, 2025, amid calls for interest rate cuts [3]. Newmont Corporation (NEM) - Newmont is actively investing in growth projects, including the Tanami Expansion 2 in Australia and the Ahafo North expansion in Ghana, aimed at increasing production capacity and extending mine life [5]. - The acquisition of Newcrest Mining Limited has enhanced Newmont's portfolio, generating $500 million in annual run-rate synergies and creating a multi-decade production profile [6]. - Newmont has divested non-core assets, generating total after-tax cash proceeds of $4.3 billion, which includes $1.7 billion from three assets sold in March 2025 and $850 million from additional sales [7]. - The company reported liquidity of $8.8 billion at the end of Q1 2025, with operating cash flow increasing 162% year-over-year to around $2 billion [8]. - Newmont returned $1 billion to shareholders through dividends and share repurchases and reduced debt by $1 billion since the beginning of 2025, maintaining a long-term debt-to-capitalization ratio of around 20% [10]. Kinross Gold Corporation (KGC) - Kinross has a strong production profile with key projects like Great Bear in Ontario and Round Mountain Phase X in Nevada, expected to enhance production and cash flow [11]. - Tasiast and Paracatu are the main contributors to Kinross's cash flow, with Tasiast being the lowest-cost asset and achieving record production in 2024 [12]. - Kinross ended Q1 2025 with liquidity of approximately $2.3 billion and generated record free cash flows of around $1.3 billion in 2024 [13]. - The company repaid $800 million of debt in 2024, reducing net debt to around $540 million, with a long-term debt-to-capitalization ratio of 14.4% [14]. Stock Performance and Valuation - Year-to-date, NEM stock has increased by 46.5%, while KGC stock has risen by 66.8%, outperforming the Zacks Mining – Gold industry's increase of 54.4% [15]. - NEM trades at a forward 12-month earnings multiple of 12.59, approximately 10% below the industry average of 14X, while KGC trades at a premium with a multiple of 13.37 [18][20]. - The Zacks Consensus Estimate for NEM's 2025 sales and EPS indicates a year-over-year rise of 2% and 20.1%, respectively, while KGC's estimates imply growth of 15.3% and 63.2% [21][24]. Investment Considerations - Both Newmont and Kinross are well-positioned to benefit from favorable gold prices, demonstrating strong financial performance and commitment to shareholder returns. Newmont is viewed as a more attractive investment due to its valuation and higher dividend yield [25].

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma Ltd. (NASDAQ: URGN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in UroGen you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/urogen-pharma-ltd-class-action-lawsuit. Investors have until July 28, 2025, to ask the Court ...

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Reddit, Inc. (NYSE: RDDT) for potential violations of the federal securities laws. If you invested in Reddit, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/reddit-inc-securities-fraud-class-action. Why is Reddit being Investigated? Reddit owns and operates the eponymous social news aggregation, forum, and social med ...

Core Viewpoint - A lawsuit has been filed against Fortrea Holdings Inc. and its senior executives for potential violations of federal securities laws, stemming from allegations of overstating cost savings and revenue projections related to transition services agreements following its spin-off from Labcorp [1][2][4]. Group 1: Company Background - Fortrea Holdings Inc. is a global contract research organization that provides biopharmaceutical product and medical device development solutions. It was spun off into a standalone, publicly traded company by Labcorp Holdings Inc. in June 2023 [3]. Group 2: Allegations and Lawsuit Details - The lawsuit claims that Fortrea overstated the cost savings and margin improvements expected from exiting transition services agreements with Labcorp, as well as the revenue from pre-spin projects [4]. - The case is pending in the U.S. District Court for the Southern District of New York, titled Deslande v. Fortrea Holdings Inc., et al., No. 1:25-cv-04630 [2]. Group 3: Stock Performance and Market Reaction - Following a report from Jefferies on September 25, 2024, which indicated that Fortrea's anticipated cost savings were not as significant as previously thought, the stock price fell by $2.73, or over 12%, from $22.21 to $19.48 per share [5]. - On March 3, 2025, Fortrea announced disappointing Q4 and full year 2024 financial results, leading to a further decline in stock price by $3.47, or over 25%, from $13.85 to $10.38 per share [6].

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elevance Health, Inc. (NYSE: ELV) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elevance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elevance-health-inc. Investors have until July 11, 2025, to ask the Court to be appointed t ...

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Compass Diversified Holdings and Compass Group Diversified Holdings, LLC (NYSE: CODI) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Compass you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/compass-diversified-holdings. Investors ...